Kayla OToole

Dr. Kayla OToole

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
SHSheri Holmen
Sheri Holmen
Aberrant activation of the PI3K–AKT pathway is common in many cancers, including melanoma, and AKT1, 2 and 3 (AKT1–3) are bona fide oncoprotein kinases with well-validated downstream effectors. However, efforts to pharmacologically inhibit AKT have proven to be largely ineffective. In this study, we observed paradoxical effects following either pharmacologic or genetic inhibition of AKT1–3 in melanoma cells. Although pharmacological inhibition was without effect, genetic silencing of all three AKT paralogs significantly induced melanoma cell death through effects on mTOR. This phenotype was rescued by exogenous AKT1 expression in a kinase-dependent manner. Pharmacological inhibition of PI3K and mTOR with a novel dual inhibitor effectively suppressed melanoma cell proliferation in vitro and inhibited tumor growth in vivo. Furthermore, this single-agent–targeted therapy was well-tolerated in vivo and was effective against MAPK inhibitor–resistant patient-derived melanoma xenografts. These results suggest that inhibition of PI3K and mTOR with this novel dual inhibitor may represent a promising therapeutic strategy in this disease in both the first-line and MAPK inhibitor–resistant setting.

18 June 2026 in Cancer Research
Verified
Journal Article
Closed access
MFMona Foth
Mona Foth
WKWontak Kim
Wontak Kim
KOKayla OToole
Kayla OToole
BMBrandon Murphy
Brandon Murphy
Montserrat Justo-GarridoMontserrat Justo-Garrido
Montserrat Justo-Garrido
MMMartin McMahon
Martin McMahon
Most patients with advanced BRAF- or NRAS-driven melanoma receive first-line immunotherapy. However, if immunotherapy fails, BRAF-mutated patients receive effective second-line therapies, whereas NRAS-mutated patients lack pathway-targeted options. Recently, RAS(ON) multiselective inhibitors like RMC-7977 and the investigational agent daraxonrasib were described that inhibit RAS[GTP] signaling in partnership with cyclophilin A (CYPA). In this study, we found that both compounds demonstrated potent antiproliferative activity against NRAS-mutated melanoma cell lines and robust antitumor activity against preclinical melanoma models. However, in preclinical models, resistance to RMC-7977 monotherapy arose through mutations in Ppia (encoding CYPA) or Map2k1 (encoding MEK1). Moreover, 2 clinical case studies in patients with NRAS-mutated melanoma treated with daraxonrasib demonstrated clear antitumor activity in 1 patient but progressive disease in another with co-occurring NRAS and MAP2K1 mutations at baseline. These findings support the potential for daraxonrasib in the treatment of patients with NRAS-mutated melanoma and reveal candidate mechanisms of monotherapy resistance, underscoring the need for combination therapies to improve outcomes. Significance: Inhibition of RAS signaling with RMC-7977 or daraxonrasib displays potent activity in models of NRAS-driven melanoma, with drug resistance mediated by mutational silencing of CYPA expression or activation of MEK1.

Verified
Journal Article
Open access
PDF file
KOKayla OToole
Kayla OToole
BRBrandon Roan
Brandon Roan
THTimothy HARDMAN
Timothy HARDMAN
PPPeyton P. Phillips
Peyton P. Phillips
EVEvan VanBrocklin
Evan VanBrocklin
SHSheri Holmen
Sheri Holmen
Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes preclinical and clinical evidence on the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, emphasizing mechanisms of blood–brain barrier traversal, tumor-stroma co-option, and brain-specific genomic and transcriptional programs. We summarize advances in therapeutic strategies to combat melanoma brain metastasis including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.

25 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KOKayla OToole
Kayla OToole
AMAdamaris Martinez
Adamaris Martinez
BMBrandon Murphy
Brandon Murphy
APAnastasia Proveyeka
Anastasia Proveyeka
GFGabriela Fort
Gabriela Fort
MMMartin McMahon
Martin McMahon
Melanoma is a highly aggressive and frequently metastatic cancer with its incidence reported to be on the rise. Although most oncogenic drivers in melanoma converge on activation of the RAS>RAF>MEK>ERK MAPK signaling pathway, not all MAPK-activating mutations are recurrently observed in this disease, suggesting a unique functional role for BRAF V600E , which is present in ∼50% of all melanoma cases. However, the prevalence of BRAF V600E alterations over other known MAPK-promoting oncoproteins raises questions regarding whether BRAF V600E possesses additional functions outside of MAPK pathway activation. Thus, we performed TurboID to differentiate the interactome between wild-type BRAF and BRAF V600E . We identified novel interacting partners of normal vs. BRAF V600E , most strikingly being the tumor suppressor TP53. While TP53 is commonly altered or lost across many malignancies, it is notable that TP53 alterations are rare in melanoma. Our studies suggest that BRAF V600E can interact with and inactivate TP53, thus providing potential mechanistic explanation as to why TP53 inactivation or loss is infrequent in BRAF V600E -driven melanoma.

15 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
GPGennie Parkman
Gennie Parkman
TTTursun Turapov
Tursun Turapov
DKDavid A. Kircher
David A. Kircher
WBWilliam J. Burnett
William J. Burnett
CSChristopher Stehn
Christopher Stehn
MMMartin McMahon
Martin McMahon
Aberrant activation of the PI3K-AKT pathway is common in melanoma but efforts to drug this pathway have proven largely ineffective in patients. In this study, we observed that pharmacological inhibition of AKT was ineffective whereas genetic silencing of all three AKT paralogs significantly abrogated melanoma cell growth through effects on mTORC signaling. This phenotype could be rescued by overexpression of AKT but was dependent on kinase activity. Interestingly, expression of the serine/threonine kinase SGK1 was increased following genetic suppression of AKT but only expression of activated SGK1 could rescue the lethal effect of AKT knockdown. SGK1 also increases tumor growth and decreases survival in a BRAF V600E -driven mouse model of melanoma. Pharmacological inhibition of SGK and AKT reduced cell proliferation. These results demonstrate that SGK1 can compensate for AKT loss in this context and suggest that dual targeting of SGK1 and AKT may represent a novel therapeutic strategy in this disease. SIGNIFICANCE: Although the AKT1, 2 & 3 genes encode: Bona fide oncoprotein kinases; well-validated downstream effectors of PI3’-lipids and: pleiotropic regulators of numerous aberrant properties of cancer cells, their role in melanoma progression and/or maintenance is poorly understood. Here we explore the effects of genetic or pharmacological inhibitors of AKT1-3 and conclude that combined inhibition of AKT plus the related SGK protein kinases may be required to inhibit melanomagenesis.

7 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
KOKayla OToole
Kayla OToole
BRBrandon Roan
Brandon Roan
THTimothy HARDMAN
Timothy HARDMAN
PPPeyton P. Phillips
Peyton P. Phillips
EVEvan VanBrocklin
Evan VanBrocklin
SHSheri Holmen
Sheri Holmen
Melanoma, a highly aggressive and metastatic cancer, poses significant challenges due to its propensity to spread to distant organs, with brain metastasis representing a particularly devastating complication. This review synthesizes recent advances in understanding the molecular, cellular, and microenvironmental mechanisms driving melanoma metastasis, with a specific emphasis on brain metastasis. We explore the unique challenges of brain metastasis, including blood-brain barrier penetration, brain-specific microenvironment interactions, and genomic distinctions. Advances in diagnostic tools, such as imaging and liquid biopsies, are discussed alongside current and emerging therapeutic strategies, including novel small molecules, immunotherapies, and combination approaches tailored for brain metastases. The review also highlights the immunological landscape of the brain, translational models, and multidisciplinary clinical management strategies. Finally, we identify critical research gaps, including the need for brain metastasis-specific clinical trials, AI-driven predictive models, and preventive strategies, to guide future efforts in improving outcomes for patients with melanoma brain metastasis.